Methyl Donors, Homocysteine, and Atrial Fibrillation: Is There a Role for TMG?
Atrial fibrillation (AF) remains one of the most common and clinically challenging arrhythmias encountered in practice. While conventional management focuses on rate/rhythm control, anticoagulation, and risk factor modification, there is increasing interest in upstream metabolic contributors—particularly those influencing inflammation, oxidative stress, and structural remodelling of the atria.
One such pathway is methylation biology, and specifically the role of homocysteine. This raises an obvious question: could methyl donors such as trimethylglycine (TMG, also known as betaine) have a therapeutic role in AF?
The short answer is: mechanistically plausible, clinically unproven.
Homocysteine and Atrial Fibrillation: A Consistent Association
The strongest signal in the literature is not with TMG itself, but with elevated homocysteine.
Large observational cohorts have demonstrated an association between higher homocysteine levels and incident AF. For example, analysis from the ARIC cohort found that elevated homocysteine was associated with increased AF risk, while higher B-vitamin status showed a trend toward reduced risk (though not consistently statistically significant)
http://pmc.ncbi.nlm.nih.gov/articles/PMC6150836/
In addition, multiple studies have linked elevated homocysteine with AF recurrence following rhythm control strategies. A 2022 analysis highlighted that higher total homocysteine levels were strongly correlated with recurrence after cardioversion or ablation
http://pmc.ncbi.nlm.nih.gov/articles/PMC9514121/
This positions homocysteine less as a causal agent and more as a marker—or mediator—of an adverse atrial substrate.
Mechanistic Rationale: Where TMG Fits
TMG (betaine) functions as a methyl donor via the enzyme betaine–homocysteine methyltransferase (BHMT), facilitating the conversion of homocysteine back to methionine. Beyond this, it also acts as an osmolyte and has broader roles in cellular stress regulation.
Comprehensive reviews describe betaine’s involvement in:
homocysteine metabolism
oxidative stress modulation
inflammatory signalling
endothelial function
lipid metabolism
http://pmc.ncbi.nlm.nih.gov/articles/PMC8224793/
Within the context of AF, these pathways intersect with known drivers of arrhythmogenesis:
Endothelial dysfunction → impaired nitric oxide signalling
Oxidative stress → ion channel instability and atrial ectopy
Inflammation → structural remodelling
Fibrosis → substrate for re-entry circuits
From a systems perspective, methyl donor support could theoretically act upstream, influencing the atrial environment rather than the arrhythmia directly.
What Does the Clinical Data Say About TMG?
This is where the hypothesis weakens.
TMG has been consistently shown to lower homocysteine levels. Meta-analyses and controlled trials demonstrate reductions typically in the range of 5–20%, depending on dose and baseline levels
http://europepmc.org/article/pmc/3610948
A 2023 randomized controlled trial combining low-dose B vitamins with betaine also demonstrated significant reductions in plasma homocysteine
http://pmc.ncbi.nlm.nih.gov/articles/PMC9886420/
However, there is a critical gap:
There are no high-quality randomized trials demonstrating that TMG reduces:
AF incidence
AF burden
AF recurrence post-ablation or cardioversion
AF-related stroke risk
In other words, we can modify the biomarker, but we have not yet demonstrated a meaningful clinical outcome.
Important Caveats
TMG is not universally benign.
Some studies have shown that while lowering homocysteine, betaine supplementation may increase LDL cholesterol and triglycerides in certain populations
http://pmc.ncbi.nlm.nih.gov/articles/PMC1140947/
There is also ongoing discussion around the trimethylamine-N-oxide (TMAO) pathway. Betaine metabolism can intersect with gut microbial production of TMAO, a molecule associated—though not definitively causally—with cardiovascular risk
http://www.frontiersin.org/articles/10.3389/fmolb.2022.964624/full
These factors complicate the simplistic view of methyl donors as purely cardioprotective.
Where This Fits Clinically
Current AF management guidelines from organizations such as the American Heart Association emphasize:
weight reduction
blood pressure control
alcohol moderation
treatment of sleep apnoea
cardiometabolic optimisation
Methyl donor therapy is not included.
However, from a functional or systems-based perspective, there is a reasonable argument for targeted use of TMG in specific subgroups:
elevated homocysteine
suboptimal folate, B12, or B6 status
MTHFR polymorphisms
metabolic syndrome
chronic inflammatory states
In these contexts, TMG may be better viewed as a metabolic optimisation strategy rather than an arrhythmia treatment.
A Balanced Interpretation
TMG has a plausible role in modifying upstream contributors to atrial fibrillation, particularly in patients with hyperhomocysteinaemia. Its effects on methylation, oxidative stress, and endothelial function provide a coherent mechanistic rationale. However, clinical evidence remains indirect, and there are currently no trials demonstrating that TMG reduces AF incidence, burden, or recurrence.
Until such data emerges, its use should remain targeted, individualised, and framed appropriately within a broader risk-reduction strategy.